A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1831-1838

  Dasgupta, Alakananda ^a   Mahapatra, Manoranjan ^a   Saxena, Renu ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chronic lymphocytic leukemia; Kaplan Meier estimates; Optimal cut off; Overall survival; Prognostic marker; Receiver operating characteristic analysis; Regulatory T cell; Time to first treatment

Indexed keywords

PROTEIN KINASE ZAP 70; TRANSCRIPTION FACTOR FOXP3; CD38 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LOW RISK PATIENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SENSITIVITY AND SPECIFICITY; IMMUNOLOGY; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TIME FACTOR;

AGED; ANTIGENS, CD38; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROGNOSIS; RESEARCH DESIGN; ROC CURVE; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84932174494     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.966245     Document Type: Article

References (48)

1. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
2. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4 CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-1253.
3. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
4. Dasgupta A, Saxena R. Regulatory T cells: A review. Natl Med J India 2012; 25: 341-351.
5. Beyer M, Kochanek M, Darabi K, et al. R educed frequencies and suppressive function of CD4 CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy withfludarabine. Blood 2005; 106: 2018-2025.
6. Dasgupta A, Mahapatra M, Saxena R. Flow cytometric immunophenotyping of regulatory T cells in chronic lymphocytic leukemia: comparative assessment of various markers and use of novel antibody panel with CD127 as alternative to transcription factor FoxP3. Leuk Lymphoma 2013; 54: 778-789.
7. Ghia P, Ferreri A M, Caligaris-Cappio F. C hronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007; 64: 234-246.
8. Chiorazzi N, Rai K R, Ferrarini M. C hronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
9. Hallek M, Cheson B D, Catovsky D, et al. G uidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
10. Binet J-L, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 859-861.
11. Scrivener S, Goddard R V, Kaminski E R, et al. A bnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003; 44: 383-389.
12. Christopoulos P, Pfeifer D, Bartholomé K, et al. D efinition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117: 3836-3846.
13. Riley R D, Hayden J A, Steyerberg E W, et al. P rognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013; 10: e1001380.
14. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009; 115: 363-372.
15. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
16. Schroers R, Griesinger F, Tr ü mper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 750-758.
17. Nipp R D, Volkheimer A D, Davis E D, et al. C D38 variation as a prognostic factor in chronic lymphocytic leukemia. Leuk Lymphoma 2014; 55: 191-194.
18. Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006; 17: 683-690.
19. Biancotto A, Dagur PK, Fuchs JC, et al. Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. Mod Pathol 2012; 25: 246-259.
20. D' A rena G, Laurenti L, Minervini M M, et al. R egulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011; 35: 363-368.
21. Deutsch V, Perry C, Polliack A. E xpansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced " brakes " on host immunity. Leuk Lymphoma 2009; 50: 687-688.
22. Jak M, Mous R, Remmerswaal E BM, et al. E nhanced formation and survival of CD4 CD25hi Foxp3 T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 788-801.
23. Giannopoulos K, Schmitt M, Kowal M, et al. C haracterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20: 677-682.
24. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 T reg cells. J Exp Med 2006; 203: 1701-1711.
25. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-1700.
26. Bewick V, Cheek L, Ball J. S tatistics review 13: receiver operating characteristic curves. Crit Care 2004; 8: 508-512.
27. D' A rena G, D' A uria F, Simeon V, et al. A shorter time to thefirst treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 2012; 87: 628-631.
28. Weiss L, Melchardt T, Egle A, et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011; 117: 2163-2169.
29. Badoual C, Hans S, Fridman WH, et al. Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 2009; 27: e5-e6; author reply e7.
30. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3 T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-192.
31. Hemingway H, Croft P, Perel P, et al. Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes. BMJ 2013; 346: e5595.
32. Steyerberg EW, Moons KGM, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013; 10: e1001381.
33. Hingorani AD, Windt DA van der, Riley RD, et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 2013; 346: e5793.
34. Simon R, A ltman D G. S tatistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979-985.
35. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-391.
36. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
37. Piper K P, Karanth M, McLarnon A, et al. C hronic lymphocytic leukaemia cells drive the global CD4 T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4 forkhead box P3 T cells. Clin Exp Immunol 2011; 166: 154-163.
38. D' Arena G, Simeon V, D' Auria F, et al. Regulatory T-cells in chronic lymphocytic leukemia: Actor or innocent bystander? Am J Blood Res 2013; 3: 52-57.
39. Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD4 CD25 regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111: 5359-5370.
40. Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009; 15: 3325-3332.
41. D' Arena G, Rossi G, Minervini MM, et al. Circulating regulatory T cells in " clinical " monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 2011; 24: 915-923.
42. Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: The future of cancer immunotherapy? Br J Cancer 2009; 100: 1697-1703.
43. D' Arena G, Deaglio S, Laurenti L, et al. Targeting regulatory T cells for anticancer therapy. Mini Rev Med Chem 2011; 11: 480-485.
44. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: The right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7: 880-887.
45. Zhou L, Chong MMW, Littman DR. Plasticity of CD4 T cell lineage differentiation. Immunity 2009; 30: 646-655.
46. McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011; 186: 3918-3926.
47. Johnston JB. Jump-starting the T cells in CLL. Blood 2013; 121: 4016-4017.
48. Stamatopoulos B, Meuleman N, De Bruyn C, et al. A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS One 2010; 5: pii: e12780.